Taken together, this work revealed that JNK/c-Jun-ATF2/Galectin-1 is a valuable target to overcome CDDP resistance in liver cancer and proposed a feasible approach to trace JNK activity in vivo. The gene discussed is ATF2; the disease is liver cancer.